Tag: 上海哪里有新茶服务

Balliol JCR names meeting after student

first_imgBalliol JCR passed a ‘funny’ motion to officially name their meeting after a current student. The meeting, held last Sunday, is now known as ‘The Susie Deedigan Memorial General Meeting.’Although a contributor to JCR meetings throughout her Oxford Career, Susie couldn’t attend this final one. In her absence, the motion noted ‘her limitless loyalty to, and enthusiasm for, debate, democracy and General Meetings’ and sought to reward ‘loyalty and enthusiasm’ in the JCR. The motion passed without opposition.The motion was proposed by two Balliol JCR committee members, Hannah Smith and Issac Rose.Smith, Vice President of Balliol JCR, told Cherwell ‘The Susie Deedigan (2010-2013) Memorial GM was a huge success. As usual there were lots of people at the GM, and everyone found it funny.’Rose commented ‘The motion, while light-hearted in tone conveyed a serious point – it was a nod of thanks to Susie who has spent the last three years both involved with and committed to the JCR.’Rose went on to say that the motion confirms Balliol JCR as ‘unique in Oxford in what it does for its students and this would not be the case were it not for people like Susie.’Yet not all JCR members found the motion funny. One Balliol student, who wishes to remain anonymous told Cherwell that ‘not many people in Balliol knew about [the motion] or have talked about it.. It’s a joke (and not everyone found it funny).’ Despite wishing to commemorate the work of a dedicated student, even the proposers of the motion seemed surprised that it has reached the press “To be honest, it’s astonishing that you find this newsworthy” said Rose. Smith agreed “it’s rather perplexing how you could think this is even a story.”last_img read more

Proposed juveniles rules changes

first_img P roposed juveniles rules changes The Florida Bar’s Juvenile Court Rules Committee has filed with the Florida Supreme Court its regular-cycle report of proposed amendments to the Florida Rules of Juvenile Procedure. The committee proposes amendments to rules 8.045 (Notice to Appear); 8.090 (Speedy Trial); 8.135 (Correction of Disposition or Commitment Orders); 8.210 (Parties and Participants); 8.257 (General Magistrates); 8.350 (Placement of Child Into Residential Treatment Center After Adjudication of Dependency); 8.515 (Providing Counsel to Parties); and 8.535 (Postdisposition Hearings) and forms 8.911 (Uniform Child Custody Jurisdiction and Enforcement Act Affidavit); 8.930 (Juvenile Notice to Appear); 8.964 (Dependency Petition); 8.966 (Adjudication Order – Dependency); 8.980 (Petition for Termination of Parental Rights Based on Voluntary Relinquishment); 8.981 (Petition for Involuntary Termination of Parental Rights); 8.983 (Adjudication Order and Judgment of Involuntary Termination of Parental Rights); and new form 8.975 (Dependency Order Withholding Adjudication). The court invites all interested persons to comment on the committee’s proposed amendments, which are summarized below and reproduced in full online at www.floridasupremecourt.org/decisions/proposed.shtml. An original and nine paper copies of all comments must be filed with the court on or before April 3, with a certificate of service verifying that a copy has been served on Alan Abramowitz, committee chair, 400 West Robinson St., Orlando 32801-1782, as well as a separate request for oral argument if the person filing the comment wishes to participate in oral argument, which may be scheduled in this case for June. The committee chair has until April 18, 2006, to file a response to any comments filed with the court. Electronic copies of all comments also must be filed in accordance with In re Mandatory Submission of Electronic Copies of Documents, Fla. Admin. Order No. AOSC04-84 (Sept. 13, 2004). IN THE SUPREME COURT OF FLORIDA IN RE: AMENDMENTS TO THE FLORIDA RULES OF JUVENILE PROCEDURE (THREE YEAR CYCLE), CASE NO. SC06-140 PROPOSED AMENDMENTS March 1, 2006 Regular News Proposed juveniles rules changeslast_img read more

Hydroxychloroquine ineffective against mild COVID-19, US study shows

first_img“Hydroxychloroquine did not substantially reduce symptom severity or prevalence over time in non-hospitalized persons with early COVID-19,” the researchers wrote in an article to be published in the Annals of Internal Medicine journal on Thursday.The randomized, placebo-controlled study was conducted on 491 non-hospitalized patients. Owing to test shortages in the United States, only 58% of participants were tested for the disease.Although it was not an endpoint of the study, five individuals who were given hydroxychloroquine were hospitalized or died because of COVID-19, compared with eight people given a placebo.The study “provides strong evidence that hydroxychloroquine offers no benefit in patients with mild illness,” Dr. Neil Schluger of New York Medical College said in an commentary on the study, also scheduled to be published on Thursday.Vocal support from Trump raised expectations for the decades-old drug. In March, Trump said hydroxychloroquine used in combination with the antibiotic azithromycin had “a real chance to be one of the biggest game changers in the history of medicine” with little evidence to back up that claim. He later said he took the drugs preventively after two people who worked at the White House were diagnosed with COVID-19.But several placebo-controlled studies suggest the drug is ineffective to either treat or prevent the disease.”There’s just more and more data accumulated that hydroxychloroquine, at least alone does not really have any effect,” said Dr. David Boulware, the senior investigator of the trial at the University of Minnesota. “Most sort of sensible people have started to move on and really look at other therapies.”Topics : The anti-malaria drug touted by US President Donald Trump as a COVID-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.About 24% of the patients given hydroxychloroquine in the study had persisting symptoms over a 14-day period, while roughly 30% of the group given a placebo were determined to have persistent symptoms over the same period.The difference was not statistically significant, the researchers said.last_img read more